Mirum Pharmaceuticals Provides Development Program Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Wall Street ends mixed as investors focus on tech earnings
Citi Reiterates Buy Rating on Mirum (MIRM), PT $34, 'Volixibat ICP Trial Discontinued, PSC and PBC Readouts Remain On Track'
November 29, 2022 9:05 AM ESTCiti analyst David Lebowitz reiterated a Buy rating and $34.00 price target on Mirum Pharamceuticals (NASDAQ: MIRM)
The analyst comments "Today, Mirum announced the discontinuation of Phase IIb OHANA study of volixibat in intrahepatic cholestasis of pregnancy (ICP) due to challenges in... More
